The Importance of MMR Immunization in the United States Olivia Perrone, MD, H

Total Page:16

File Type:pdf, Size:1020Kb

The Importance of MMR Immunization in the United States Olivia Perrone, MD, H The Importance of MMR Immunization in the United States Olivia Perrone, MD, H. Cody Meissner, MD Despite the established safety and efficacy of the measles-mumps-rubella abstract vaccine after almost 50 years of widespread use, the United States is encountering higher levels of measles and mumps disease than has occurred for years. Return of disease threatens the health of those who remain unimmunized by choice as well as those who are immunized appropriately but experience loss of vaccine-induced immunity. The solution to continued threats of illness caused by these untreatable but readily preventable diseases is compliance with recommendations for administration of the measles- mumps-rubella vaccine. Here we examine trends in the epidemiology of measles, mumps, and rubella in recent years and consider the consequences of loss of protective immunity within our country. Department of Pediatrics, School of Medicine, Tufts University and Tufts Medical Center, Boston, Massachusetts Growing concern among health care ∼97% effective in prevention of clinical Drs Perrone and Meissner conceptualized and designed the study, drafted the initial manuscript, professionals and the public regarding disease and is considered to provide fi 2 reviewed the revised manuscript, approved the nal the severity and the contagiousness of lifelong protection against rubella. In manuscript as submitted, and agree to be measles and mumps, 2 previously view of the availability of MMR, a safe accountable for all aspects of the work. controlled diseases in the United States, and effective vaccine, why does disease DOI: https://doi.org/10.1542/peds.2020-0251 has focused attention on the role of the still occur, and what can be done to Accepted for publication May 5, 2020 measles-mumps-rubella vaccine control the spread of measles, to (MMR). The number of reported control the outbreaks of mumps, and to Address correspondence to H. Cody Meissner, MD, Department of Pediatrics, School of Medicine, Tufts measles, mumps, and rubella cases sustain the elimination of rubella? University and Tufts Medical Center, 800 Washington decreased by .95% after introduction St, Boston, MA 02111. E-mail: cmeissner@ of each monovalent vaccine, yet disease tuftsmedicalcenter.org continues to occur nearly 50 years after MEASLES PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, the 3 vaccines were combined into Before measles vaccines were licensed 1098-4275). a single trivalent vaccine in 1971. in 1963, childhood infection with Copyright © 2020 by the American Academy of Measles occurs mainly among measles was nearly universal, resulting Pediatrics unimmunized people exposed to in an estimated 3 to 4 million cases FINANCIAL DISCLOSURE: The authors have indicated fi a contagious traveler who arrives from annually (the birth cohort), .500 they have no nancial relationships relevant to this article to disclose. a country outside the United States deaths, and thousands of cases of 1,2 FUNDING: where measles virus is circulating. measles-associated encephalitis in the No external funding. Mumps outbreaks occur after exposure United States.1 After licensure of the POTENTIAL CONFLICT OF INTEREST: Dr Meissner fi to an index case in settings where first measles vaccines, the incidence of serves as ex-of cio to the Committee on Infectious Diseases, is a member of the National Vaccine people have close, prolonged contact, disease declined rapidly. By 2000, the such as universities or close-knit Advisory Committee, is a member of the Vaccine and United States was certified to be free of Related Biological Products Advisory Committee, and communities, and may or may not have measles, meaning that after is chair of the Vaccine Injury Compensation Program; 2–4 received 2 doses of MMR. The importation of a case, no continuous and Dr Perrone has indicated she has no potential fl attenuated rubella virus contained in transmission occurred for at least 12 con icts of interest to disclose. MMR (Wistar RA 27/3) is more months. Between 1997 and 2013 the effective at inducing protective incidence of measles remained To cite: Perrone O and Meissner HC. The immunity than the measles or mumps remarkably low at ,1 case per 1 Importance of MMR Immunization in the United States. Pediatrics. 2020;146(2):e20200251 vaccine strains, and a single dose is million population.1 Starting in 2014, Downloaded from www.aappublications.org/news by guest on October 4, 2021 PEDIATRICS Volume 146, number 2, August 2020:e20200251 SPECIAL ARTICLE the number of cases increased, and in because of high 2-dose immunization among children who experience 2019, .1250 cases of measles were rates of MMR (that results in high measles than among children who are reported, representing the highest rates of immunity in the community) not infected. This has been attributed number in 17 years.5 Approximately and the rapid implementation of to suppression of innate and adaptive 90% of reported cases occurred control measures from state and local immunity that is associated with among people who were health departments. However, these natural measles virus infection.12 unvaccinated (70%) or whose control measures are costly and draw Some immunologic abnormalities vaccination status was unknown resources away from other critical resolve soon after infection, but (20%).5 public health responsibilities.8 epidemiological studies demonstrate a strong association between measles In the United States, a single dose of In the absence of antiviral therapy, virus infection and increased a measles-containing vaccine treatment of measles consists of morbidity and mortality for months administered at 12 months of age has management of dehydration and to years after infection. In recent a vaccine effectiveness of ∼93% (and nutritional deficiencies (including reports, authors describe immune 97% when administered at vitamin A) and antimicrobial therapy abnormalities that appear to explain 15 months of age). Primary measles if secondary bacterial infections this increased risk of infection after vaccine failure (lack of occur. Approximately 30% of – recovery from measles.13 15 During seroconversion) occurs in ∼2% to 5% reported measles cases result in one an outbreak of measles in the of vaccine recipients who receive 1 of the following complications: Netherlands, unvaccinated children dose of the vaccine. Primary vaccine diarrhea, otitis media, pneumonia, were evaluated before measles failure may be caused by passive and less commonly, acute infection and again 2 months after antibodies in the vaccine recipient at encephalitis, degenerative neurologic recovery. Results revealed an the time of immunization (such as disease (subacute sclerosing impaired adaptive immune response, residual maternal antibodies), panencephalitis [SSPE]), or death.1 as evidenced by an 11% to 73% loss a damaged vaccine, or incorrect SSPE is an invariably fatal, persistent of antibody repertoire, after measles records (ie, administration of the viral infection of neuronal and glial infection. This appears to be incorrect vaccine). Secondary measles cells caused by a defective virus that secondary to measles virus vaccine failure (waning antibody occurs after a wild-type measles replication in and destruction of both concentrations to unprotective levels infection, particularly among children naïve and memory B cells, cells after an initial response) seldom who are infected in the first few years responsible for production of occurs. More than 98% of people who of life. Reports from the prevaccine circulating and secreted antibodies. receive $2 doses of a measles- era suggested rates of SSPE of 5 to 10 This loss of humoral immunity leaves containing vaccine, according to the cases per 1 million measles cases.1,9 children at an increased risk for recommended immunization This figure is considered now to be an infection from pathogens to which schedule, develop serological underestimation because an average they previously had been immune evidence of immunity.1 The second of 6 to 10 years occurs between the because of infection or vaccination. MMR dose is not a booster dose; measles infection and the onset of Recovery of lost immunity was rather, it is intended to induce symptoms of SSPE, making an restored after reexposure to immunity in the small number of association difficult to discern. In pathogens. Remarkably, despite this people who do not develop protective studies after the 1989–1991 measles immunosuppression, lifelong immunity after the first dose. outbreak in the United States and immunity to measles develops among Europe, authors report that the rate The number of measles cases survivors of acute measles infection. of SSPE is more common than occurring in the United States in Measles vaccination is not associated estimated previously, at least 1 case a given year is determined by 2 with the immunologic deficits of SSPE per 5000 measles cases, and factors: first, the number of travelers associated with wild-type measles is perhaps as common as 1 case per who become infected abroad and infection. 1000 measles cases among children travel to or return to this country infected in the first year of life.10,11 In while contagious; and second, the The consequences to a community countries where appropriate measles number of susceptible people who that does not maintain vaccine- immunization programs have been are exposed to the traveler.6,7 Clusters induced protective immunity (herd established, SSPE is nearly of disease are more likely to occur in immunity) to measles can be undetectable. communities with pockets of dramatic. In September 2019, several unvaccinated people. The majority of In reports from countries in Africa cases of suspected measles were importations have not resulted in and elsewhere, authors describe reported in the Samoan islands, and larger outbreaks in the United States higher morbidity and mortality rates by October 2019, a national measles Downloaded from www.aappublications.org/news by guest on October 4, 2021 2 PERRONE and MEISSNER outbreak was declared. By January 7, MMR confer long-lived immunity others at increased risk of 2020, a total of 5655 cases were and meet the CDC definition of exposure do not have written reported in the Independent State of immune.
Recommended publications
  • Communicable Disease Chart
    COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious;
    [Show full text]
  • COVID-19 Natural Immunity
    COVID-19 natural immunity Scientific brief 10 May 2021 Key Messages: • Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies. • The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). • Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immune responses is under investigation by researchers around the world. • There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood. Objective of the scientific brief This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.1 This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considerations on vaccine certificates or “passports”will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.2 Methods A rapid review on the subject was undertaken and scientific journals were regularly screened for articles on COVID-19 immunity to ensure to include all large and robust studies available in the literature at the time of writing.
    [Show full text]
  • Mumps Virus Pathogenesis Clinical Features
    Mumps Mumps Mumps is an acute viral illness. Parotitis and orchitis were described by Hippocrates in the 5th century BCE. In 1934, Johnson and Goodpasture showed that mumps could be transmitted from infected patients to rhesus monkeys and demonstrated that mumps was caused by a filterable agent present in saliva. This agent was later shown to be a virus. Mumps was a frequent cause of outbreaks among military personnel in the prevaccine era, and was one of the most common causes of aseptic meningitis and sensorineural deafness in childhood. During World War I, only influenza and gonorrhea were more common causes of hospitalization among soldiers. Outbreaks of mumps have been reported among military personnel as recently as 1986. Mumps Virus Mumps virus is a paramyxovirus in the same group as parainfluenza and Newcastle disease virus. Parainfluenza and Newcastle disease viruses produce antibodies that cross- 11 react with mumps virus. The virus has a single-stranded RNA genome. The virus can be isolated or propagated in cultures of various human and monkey tissues and in embryonated eggs. It has been recovered from the saliva, cerebrospinal fluid, urine, blood, milk, and infected tissues of patients with mumps. Mumps virus is rapidly inactivated by formalin, ether, chloroform, heat, and ultraviolet light. Pathogenesis The virus is acquired by respiratory droplets. It replicates in the nasopharynx and regional lymph nodes. After 12–25 days a viremia occurs, which lasts from 3 to 5 days. During the viremia, the virus spreads to multiple tissues, including the meninges, and glands such as the salivary, pancreas, testes, and ovaries.
    [Show full text]
  • Outbreak of SARS-Cov-2 Infections, Including COVID-19 Vaccine
    Morbidity and Mortality Weekly Report Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 Catherine M. Brown, DVM1; Johanna Vostok, MPH1; Hillary Johnson, MHS1; Meagan Burns, MPH1; Radhika Gharpure, DVM2; Samira Sami, DrPH2; Rebecca T. Sabo, MPH2; Noemi Hall, PhD2; Anne Foreman, PhD2; Petra L. Schubert, MPH1; Glen R. Gallagher PhD1; Timelia Fink1; Lawrence C. Madoff, MD1; Stacey B. Gabriel, PhD3; Bronwyn MacInnis, PhD3; Daniel J. Park, PhD3; Katherine J. Siddle, PhD3; Vaira Harik, MS4; Deirdre Arvidson, MSN4; Taylor Brock-Fisher, MSc5; Molly Dunn, DVM5; Amanda Kearns5; A. Scott Laney, PhD2 On July 30, 2021, this report was posted as an MMWR Early Massachusetts, that attracted thousands of tourists from across Release on the MMWR website (https://www.cdc.gov/mmwr). the United States. Beginning July 10, the Massachusetts During July 2021, 469 cases of COVID-19 associated Department of Public Health (MA DPH) received reports of with multiple summer events and large public gatherings in an increase in COVID-19 cases among persons who reside in a town in Barnstable County, Massachusetts, were identified or recently visited Barnstable County, including in fully vac- among Massachusetts residents; vaccination coverage among cinated persons. Persons with COVID-19 reported attending eligible Massachusetts residents was 69%. Approximately densely packed indoor and outdoor events at venues that three quarters (346; 74%) of cases occurred in fully vac- included bars, restaurants, guest houses, and rental homes. On cinated persons (those who had completed a 2-dose course July 3, MA DPH had reported a 14-day average COVID-19 of mRNA vaccine [Pfizer-BioNTech or Moderna] or had incidence of zero cases per 100,000 persons per day in residents received a single dose of Janssen [Johnson & Johnson] vac- of the town in Barnstable County; by July 17, the 14-day cine ≥14 days before exposure).
    [Show full text]
  • Measles, Mumps, and Rubella
    Measles, Mumps, and Rubella Developed by Vini Vijayan, MD, in collaboration with the ANGELS Team. Last reviewed by Vini Vijayan, MD, January 24, 2017. Because measles, mumps, and rubella can be prevented by a combination vaccine, all 3 of these illnesses are discussed in this Guideline. The following vaccines are available in the United States: Live measles, mumps, and rubella virus vaccine (MMR) Live measles, mumps, rubella, and varicella virus vaccine (MMRV) MEASLES (RUBEOLA) Key Points Measles, also called rubeola or red measles, is a highly contagious viral illness characterized by fever, malaise, rash, cough, coryza (runny nose), and conjunctivitis. Measles is a leading cause of morbidity and mortality in developing countries. Over the past decade measles has been making a resurgence in the United States. Vaccination with MMR or MMRV is highly effective in preventing the disease. Introduction The Virus The measles virus is a single-stranded, enveloped ribonucleic acid (RNA) virus of the genus Morbillivirus within the family Paramyxoviridae. 1 The virus enters the respiratory epithelium of the nasopharynx and regional lymph nodes resulting in viremia and dissemination to the skin, respiratory tract, and other organs. The peak incidence of measles in temperate areas is late winter and early spring. Transmission Measles is a highly contagious virus with an estimated 90% secondary infection rate in susceptible domestic contacts. Measles is spread by droplets from respiratory secretions and close personal contact or direct contact with infected nasal or throat secretions. Measles virus can be transmitted by an infected person from 4 days prior to the onset of the rash to 4 days after the rash erupts.
    [Show full text]
  • Viruses in Transplantation - Not Always Enemies
    Viruses in transplantation - not always enemies Virome and transplantation ECCMID 2018 - Madrid Prof. Laurent Kaiser Head Division of Infectious Diseases Laboratory of Virology Geneva Center for Emerging Viral Diseases University Hospital of Geneva ESCMID eLibrary © by author Conflict of interest None ESCMID eLibrary © by author The human virome: definition? Repertoire of viruses found on the surface of/inside any body fluid/tissue • Eukaryotic DNA and RNA viruses • Prokaryotic DNA and RNA viruses (phages) 25 • The “main” viral community (up to 10 bacteriophages in humans) Haynes M. 2011, Metagenomic of the human body • Endogenous viral elements integrated into host chromosomes (8% of the human genome) • NGS is shaping the definition Rascovan N et al. Annu Rev Microbiol 2016;70:125-41 Popgeorgiev N et al. Intervirology 2013;56:395-412 Norman JM et al. Cell 2015;160:447-60 ESCMID eLibraryFoxman EF et al. Nat Rev Microbiol 2011;9:254-64 © by author Viruses routinely known to cause diseases (non exhaustive) Upper resp./oropharyngeal HSV 1 Influenza CNS Mumps virus Rhinovirus JC virus RSV Eye Herpes viruses Parainfluenza HSV Measles Coronavirus Adenovirus LCM virus Cytomegalovirus Flaviviruses Rabies HHV6 Poliovirus Heart Lower respiratory HTLV-1 Coxsackie B virus Rhinoviruses Parainfluenza virus HIV Coronaviruses Respiratory syncytial virus Parainfluenza virus Adenovirus Respiratory syncytial virus Coronaviruses Gastro-intestinal Influenza virus type A and B Human Bocavirus 1 Adenovirus Hepatitis virus type A, B, C, D, E Those that cause
    [Show full text]
  • Infection Prevention News & Updates
    APRIL 2018 INFECTION PREVENTION NEWS & UPDATES FAST FACTS HEPATITIS A Hepatitis A outbreaks continue to occur as the global prevalence appears Severity to be rapidly increasing. Victoria Australia is seeing its outbreak grow with MULTI-COUNTRY OUTBREAK 58 confirmed cases, 7 probably cases, 16 cases under early investigation, and one death. Being homeless or an IV drug user is associated with a higher probability of becoming infected. The initial laboratory analysis suggests the strain is similar to a strain circulating in Europe, suggesting Transmission CONTACT there is a travel associated case linking the outbreaks. The outbreak in Kentucky in the US is continuing to grow with 150 cases, 124 of which are in the greater Louisville area. As with other outbreaks, the homeless and IV drug users are at a higher risk of getting disease. The Utah outbreak has 217 confirmed cases. Genetic sequencing of the virus has shown that the Arizona and California outbreaks reported previously are tied to these outbreaks as well. Location AUSTRALIA, USA Hepatitis A is an infection that causes an inflammation of the liver. There are a number of viruses that can cause Hepatitis including Hepatitis A, Hepatitis B, and Hepatitis C, with vaccinations available for Hepatitis A and Hepatitis B. Hepatitis A is passed to other people through contact with infected feces, or if an infected person touches objects after using the toilet and not washing their hands, including contaminating food or drink from contact with contaminated hands, so handwashing and surface disinfection are important interventions to prevent the spread of the virus. It can also be spread by sexual contact.
    [Show full text]
  • Perspectives on Vaccination Against Respiratory Syncytial Virus
    Perspectives on vaccination against respiratory syncytial virus What makes the development of RSV vaccines challenging? Oliver Wicht PhD, Projectleader MD-RSV antibodies RIVM, Centrum infektieziektenbestrijding http://www.strategischprogramma rivm.nl/gezondheid_afweer RSV is a pleomorphic paramyxovirus Jeffree et al. Virology, Volume 306, Issue 2, 2003, 254–267 ● Same family as measles virus, mumps virus, and metapneumovirus ● Vaccine is not available ● Pathogenesis varies from mild cold to bronchiolitis and pneumonia, rarely lethal ● reinfections frequently occur throughout life, 5-20% of population per annum 3 Perspectives on vaccination against RSV | 18-11-2015 RSV-mediated respiratory disease RSV infection by large droplets and contaminated surfaces virus shedding URT virus cleared 3- 5 days 1- 3 weeks Upper respiratory tract infection Rhinorrhea, cough, common cold 4 Perspectives on vaccination against RSV | 18-11-2015 RSV-mediated respiratory disease RSV infection by large droplets and Lower respiratory tract infection: contaminated surfaces Fever, malaise, headache, myalgia, sore throat, cough, dyspnea, rhinorrhea Otits, Sinositis, brochiolitis, pneumonia 1- 3 days virus shedding 4 - 8 months virus LRT URT virus cleared cleared 3- 5 days 1- 3 weeks possible longer term effects: airway hyperreactivity, wheezing, asthma 5 Perspectives on vaccination against RSV | 18-11-2015 RSV-mediated respiratory disease ● RSV stays in the lungs, usually not systemic – Mucosal pathogens are hard to study because conditions are hard to mimick in
    [Show full text]
  • SARS-Cov-2 Vaccine Breakthrough Infections Are Asymptomatic Or Mildly Symptomatic and Are Infrequently Transmitted
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.29.21259500; this version posted July 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted. Francesca Rovida1, Irene Cassaniti1, Stefania Paolucci1, Elena Percivalle1, Antonella Sarasini1, Antonio Piralla1, Federica Giardina1, Jose Camilla Sammartino1, Alessandro Ferrari1, Federica Bergami1, Alba Muzzi2, Viola Novelli2, Alessandro Meloni2,6, Anna Maria Grugnetti3, Giuseppina Grugnetti3, Claudia Rona2, Marinella Daglio2, Carlo Marena2, Antonio Triarico4, Daniele Lilleri1*, Fausto Baldanti1,5 1Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Health Professions Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Direzione Sanitaria, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; 6 Department of Public Health, Experimental and Forensic Medicine, Section of Hygiene, University of Pavia, Pavia, Italy; *Correspondence to: Daniele Lilleri; [email protected] World count: Abstract: 148 Text: 1900 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.06.29.21259500; this version posted July 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Effect of Vaccination and of Prior Infection on Infectiousness of Vaccine Breakthrough Infections and Reinfections
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.28.21261086; this version posted July 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections Laith J. Abu-Raddad, PhD1,2,3,4*, Hiam Chemaitelly, MSc1,2, Houssein H. Ayoub, PhD5, Patrick Tang, MD PhD6, Peter Coyle, MD7,8,9, Mohammad R. Hasan, PhD6, Hadi M. Yassine, PhD8,10, Fatiha M. Benslimane, PhD8,10, Hebah A. Al Khatib, PhD8,10, Zaina Al Kanaani, PhD7, Einas Al Kuwari, MD7, Andrew Jeremijenko, MD7, Anvar Hassan Kaleeckal, MSc7, Ali Nizar Latif, MD7, Riyazuddin Mohammad Shaik, MSc7, Hanan F. Abdul Rahim, PhD4, Gheyath K. Nasrallah, PhD8,10, Mohamed Ghaith Al Kuwari, MD11, Adeel A. Butt, MBBS MS3,7, Hamad Eid Al Romaihi, MD12, Abdullatif Al Khal, MD7, Mohamed H. Al-Thani, MD12, and Roberto Bertollini, MD MPH12 1Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar 2World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar 3Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA 4Department of Public Health,
    [Show full text]
  • Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine
    International Journal of Environmental Research and Public Health Review Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine Shih-Bin Su 1, Hsiao-Liang Chang 2 and Kow-Tong Chen 3,4,* 1 Department of Occupational Medicine, Chi-Mei Medical Center, Tainan 710, Taiwan; [email protected] 2 Department of Surveillance, Centers for Disease Control, Taipei 100, Taiwan; [email protected] 3 Department of Occupational Medicine, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan 701, Taiwan 4 Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan * Correspondence: [email protected]; Tel.: +886-6-2609926; Fax: +886-6-2606351 Received: 17 January 2020; Accepted: 29 February 2020; Published: 5 March 2020 Abstract: Mumps is an important childhood infectious disease caused by mumps virus (MuV). We reviewed the epidemiology, pathogenesis, and vaccine development of mumps. Previous studies were identified using the key words “mumps” and “epidemiology”, “pathogenesis” or “vaccine” in MEDLINE, PubMed, Embase, Web of Science, and Google Scholar. We excluded the articles that were not published in the English language, manuscripts without abstracts, and opinion articles from the review. The number of cases caused by MuV decreased steeply after the introduction of the mumps vaccine worldwide. In recent years, a global resurgence of mumps cases in developed countries and cases of aseptic meningitis caused by some mumps vaccine strains have renewed the importance of MuV infection worldwide. The performance of mumps vaccination has become an important issue for controlling mumps infections. Vaccine development and routine vaccination are still effective measures to globally reduce the incidence of mumps infections.
    [Show full text]
  • Mumps Outbreak — Connecticut, in This Issue
    Volume 30, No. 3 April 2010 Mumps Outbreak — Connecticut, In this issue... January – April 2010 Mumps Outbreak—Connecticut, 9 During January 2010, the Connecticut Department January — April 2010 of Public Health (DPH) identified the first mumps Outbreaks of Norovirus 10 outbreak in the state in more than 25 years. This Gastroenteritis Associated with a report summarizes the outbreak, describes the Bakery, Connecticut, 2010 relationship between the outbreak in Connecticut Figure 1: Mumps cases associated with a and a larger mumps outbreak ongoing in the Connecticut residential school (n=13) Northeast region, and provides general mumps clinical characteristics, as well as transmission and 4 vaccination information. 3 On January 28, 2010 the DPH Immunization s e s Program was notified of several possible mumps a C f o cases in a Connecticut residential school providing 2 r e secondary and post-secondary education to 72 b m u male students from a tradition-observant religious N 1 community. Shortly thereafter, a site visit was conducted, case follow-up was initiated, and additional statewide case-finding methods were 0 implemented. Cases were classified using the 2008 Jan 6 Jan 15 Jan 24 Feb 2 Feb 11 national surveillance case definition (1). On Date of Illness Onset February 5, 2010, the DPH issued a mumps advisory to raise awareness among practitioners mumps outbreak in Connecticut is epidemiologically and enhance surveillance for potential mumps linked to a larger outbreak occurring in the cases; an update was provided on March 16. Northeast region; epidemiologic linkage consisted of travel to an out-of-state area where mumps As of April 13, 2010, a total of 12 confirmed cases cases were occurring.
    [Show full text]